Belgium (BE)

The Initial Stage of Cloud Lightning Imaged in High-Resolution (2021) Scholten O, Hare BM, Dwyer J, Sterpka C, Kolmašová I, Santolík O, Lán R, et al. Journal article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Photoionization Models for High-density Gas (2021) Kallman T, Bautista M, Deprince J, Garcia J, Mendoza C, Ogorzalek A, Palmeri P, Quinet P Journal article Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial (2021) Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, et al. Journal article Halogen molecular modifications at high pressure: The case of iodine (2021) Shi J, Fonda E, Botti S, Marques MAL, Shinmei T, Irifune T, Flank AM, et al. Journal article A Full D-Band Low Noise Amplifier in 130 nm SiGe BiCMOS using Zero-Ohm Transmission Lines (2021) Maiwald T, Potschka J, Kolb K, Dietz M, Aufinger K, Visweswaran A, Weigel R Conference contribution, Conference Contribution Body posture and interpersonal perception in a dyadic interaction: A Big Two analysis (2021) Abele-Brehm A, Yzerbyt V Journal article Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient? (2021) Goto K, Schauer A, Augstein A, Methawasin M, Granzier H, Halle M, Van Craenenbroeck EM, et al. Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution